Denosumab biosimilar by Sandoz Group for Bone Metastasis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Bone Metastasis.

Source link
#Denosumab #biosimilar #Sandoz #Group #Bone #Metastasis #Likelihood #Approval